Development and validation of an HPLC-UV method for iodixanol quantification in human plasma

被引:7
作者
Chitnis, Shripad D. [1 ]
Akhlaghi, Fatemeh [1 ]
机构
[1] Univ Rhode Isl, Clin Pharmacokinet Res Lab, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 869卷 / 1-2期
关键词
assay; concentration; contrast media agent; GFR; HPLC-UV; iodixanol; iohexol; kidney function;
D O I
10.1016/j.jchromb.2008.05.002
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Iodixanol is a widely used iso-osmolar contrast medium agent. Similar to iohexol, it can also be a good exogenous marker for the measurement of glomerular filtration rate (GFR). This article describes the development and validation of an HPLC-UV method for quantification of iodixanol in human plasma. internal standard, iohexol (20 mu l, 1 mg/ml), and perchloric acid (30 mu l, 20%, v/v) were added to plasma samples (300 mu l), followed by neutralization with 10 mu l potassium carbonate (5M). Samples were centrifuged and 10 mu l of the supernatant was injected onto a C-18 EPS analytical column (3 mu m particle size, 150 mm x 4.6 mm). The extraction method yielded > 95% recovery for both iodixanol and iohexol. The mobile phase consisted of 0.1% (w/v) sodium formate buffer and acetonitrile. Iohexol and iodixanol peaks were eluted at similar to 5 and 9 min, respectively using a fast gradient method. The assay lower limit of detection was 2.0 mu g/ml and lower limit of quantification was 10 mu g/ml. The calibration curves, assessed in six replicates, were linear over an iodixanol concentration range of 10-750 mu g/ml. Intra- and inter-day accuracy was > 95% and precision expressed as % coefficient of variation was < 10%. This method is simple, accurate, precise and robust and can potentially be used for iodixanol quantification in large-scale clinical studies. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 21 条
[1]  
BOIJSEN M, 1988, ACTA RADIOL, V29, P669
[2]   An overview of the clinical pharmacokinetics of x-ray contrast media [J].
Bourin, M ;
Jolliet, P ;
Ballereau, F .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :180-193
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]   Renal tolerance of nonionic dimers [J].
Deray, G ;
Jacobs, C .
INVESTIGATIVE RADIOLOGY, 1996, 31 (06) :372-377
[6]  
Deray Gilbert, 2006, J Invasive Cardiol, V18, P84
[7]   Safety, tolerance, and pharmacokinetics of iodixanol injection, a nonionic, isosmolar, hexa-iodinated contrast agent [J].
Fountaine, H ;
Harnish, P ;
Andrew, E ;
Grynne, B .
ACADEMIC RADIOLOGY, 1996, 3 :S475-S484
[8]  
GADOJIMENEZ Y, 2006, CONTACT DERMATITIS, V55, P348
[9]  
GASPARI F, 1995, J AM SOC NEPHROL, V6, P257
[10]   On-line dialysis and quantitative high-performance liquid chromatography analysis of iodixanol in human, rat and monkey plasma [J].
Jacobsen, FB .
JOURNAL OF CHROMATOGRAPHY B, 2000, 749 (01) :135-142